For the quarter ending 2025-09-30, INDP made $2,687,575 in revenue. -$2,975,117 in net income. Net profit margin of -110.70%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 1,517,723 | 2,167,114 | ||
| General and administrative | 1,130,764 | 2,289,649 | ||
| Total operating expenses | 2,648,487 | 4,456,763 | ||
| Loss from operations | -2,648,487 | -4,456,763 | ||
| Other income, net | 39,088 | 15,547 | ||
| Change in fair value of convertible promissory notes | -365,718 | -787,703 | ||
| Net loss | -2,975,117 | -5,228,919 | ||
| Net loss available to common stockholders per share of common stock, basic | -2.98 | -9.09 | ||
| Net loss available to common stockholders per share of common stock, diluted | -2.98 | -9.09 | ||
| Weighted average number of shares used in calculating net loss per share, basic | 997,038 | 574,923 | ||
| Weighted average number of shares used in calculating net loss per share, diluted | 997,038 | 574,923 | ||
Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc. (INDP)